Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06726161 · ClinicalTrials.gov registry record · Phase 1

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable HCC

A Phase 1 study of HCC, sponsored by RayzeBio.

Recruiting
Registry status
Phase 1
Development phase
70
Enrollment target
2
Study locations

NCT06726161 is a Phase 1 study of HCC that is actively recruiting participants, run by RayzeBio. The registered enrollment target is 70 participants, below the 196-participant average among 13 other HCC trials with a reported enrollment target (64% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06726161, a Phase 1 study of HCC, is actively recruiting participants, sponsored by RayzeBio.

RECRUITING
Registry status
Phase 1
Development phase
70 participants
Enrollment target
2
Study locations

Study Summary

A single arm, open-label Phase 1/1b study of the theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable HCC

Conditions Studied

HCC

Interventions

  • DIAGNOSTIC_TEST RYZ811
  • DRUG RYZ801

Study Locations (2)

Alabama

  • Research Facility - Birmingham

Michigan

  • Research Facility - Grand Rapids

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2024-11-15
Est. Completion 2031-01
Phase Phase 1

Sponsor

RayzeBio

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06726161

The ClinicalTrials.gov registry entry for NCT06726161 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 13 other HCC trials with a reported enrollment target (64% lower). The listed sponsor is RayzeBio, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HCC appearing as the primary indexed condition, and to 2 interventions - of which RYZ811 is the first listed.

NCT06726161 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Alabama, Michigan.

Frequently Asked Questions

What is clinical trial NCT06726161 about?

NCT06726161 is a clinical study titled "Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable HCC". A single arm, open-label Phase 1/1b study of the theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable HCC

What is the current status of trial NCT06726161?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2024-11-15. Estimated completion is 2031-01.

What conditions does trial NCT06726161 study?

This clinical trial studies the following conditions: HCC.

What interventions are being tested in trial NCT06726161?

The interventions under investigation include: RYZ811 (DIAGNOSTIC_TEST), RYZ801 (DRUG).

Who is sponsoring clinical trial NCT06726161?

This trial is sponsored by RayzeBio, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06726161 being conducted?

This trial has 2 study locations across Alabama, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HCC

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HCC

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.